C4 Therapeutics Inc
NASDAQ:CCCC
C4 Therapeutics Inc
Pre-Tax Income
C4 Therapeutics Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C4 Therapeutics Inc
NASDAQ:CCCC
|
Pre-Tax Income
-$131.2m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$1.1B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-16%
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$7.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$4.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
19%
|
See Also
What is C4 Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
-131.2m
USD
Based on the financial report for Dec 31, 2023, C4 Therapeutics Inc's Pre-Tax Income amounts to -131.2m USD.
What is C4 Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-53%
Over the last year, the Pre-Tax Income growth was -2%. The average annual Pre-Tax Income growth rates for C4 Therapeutics Inc have been -25% over the past three years , -53% over the past five years .